175 related articles for article (PubMed ID: 36162136)
1. Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor.
Kwan SY; Slayden AN; Coronado AR; Marquez RC; Chen H; Wei P; Savage MI; Vornik LA; Fox JT; Sei S; Liang D; Stevenson HL; Wilkerson GK; Gagea M; Brown PH; Beretta L
Cancer Prev Res (Phila); 2023 Jan; 16(1):17-28. PubMed ID: 36162136
[TBL] [Abstract][Full Text] [Related]
2. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
[No Abstract] [Full Text] [Related]
5. Lack of FGF21 promotes NASH-HCC transition
Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
[No Abstract] [Full Text] [Related]
6. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.
Boslem E; Reibe S; Carlessi R; Smeuninx B; Tegegne S; Egan CL; McLennan E; Terry LV; Nobis M; Mu A; Nowell C; Horadagoda N; Henstridge DC; Mellett NA; Timpson P; Jones M; Denisenko E; Forrest ARR; Tirnitz-Parker JEE; Meikle PJ; Rose-John S; Karin M; Febbraio MA
Sci Adv; 2023 Sep; 9(37):eadh0831. PubMed ID: 37703359
[TBL] [Abstract][Full Text] [Related]
8. Toll-like Receptor 4 on Macrophage Promotes the Development of Steatohepatitis-related Hepatocellular Carcinoma in Mice.
Miura K; Ishioka M; Minami S; Horie Y; Ohshima S; Goto T; Ohnishi H
J Biol Chem; 2016 May; 291(22):11504-17. PubMed ID: 27022031
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.
Shimizu Y; Tamura T; Kemmochi A; Owada Y; Ozawa Y; Hisakura K; Matsuzaka T; Shimano H; Nakano N; Sakashita S; Oda T; Ohkohchi N
J Gastroenterol Hepatol; 2021 Mar; 36(3):800-810. PubMed ID: 32870526
[TBL] [Abstract][Full Text] [Related]
10. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer.
Gay MD; Safronenka A; Cao H; Liu FH; Malchiodi ZX; Tucker RD; Kroemer A; Shivapurkar N; Smith JP
Cancer Prev Res (Phila); 2021 Jan; 14(1):17-30. PubMed ID: 33115780
[TBL] [Abstract][Full Text] [Related]
12. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
[TBL] [Abstract][Full Text] [Related]
13. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma.
Muir K; Hazim A; He Y; Peyressatre M; Kim DY; Song X; Beretta L
Cancer Res; 2013 Aug; 73(15):4722-31. PubMed ID: 23749645
[TBL] [Abstract][Full Text] [Related]
14. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
Kojima M; Takahashi H; Kuwashiro T; Tanaka K; Mori H; Ozaki I; Kitajima Y; Matsuda Y; Ashida K; Eguchi Y; Anzai K
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785012
[TBL] [Abstract][Full Text] [Related]
16. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
Jühling F; Hamdane N; Crouchet E; Li S; El Saghire H; Mukherji A; Fujiwara N; Oudot MA; Thumann C; Saviano A; Roca Suarez AA; Goto K; Masia R; Sojoodi M; Arora G; Aikata H; Ono A; Tabrizian P; Schwartz M; Polyak SJ; Davidson I; Schmidl C; Bock C; Schuster C; Chayama K; Pessaux P; Tanabe KK; Hoshida Y; Zeisel MB; Duong FH; Fuchs BC; Baumert TF
Gut; 2021 Jan; 70(1):157-169. PubMed ID: 32217639
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet.
Miura K; Ohnishi H; Morimoto N; Minami S; Ishioka M; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Isoda N; Yamamoto H
Cancer Sci; 2019 Feb; 110(2):771-783. PubMed ID: 30520543
[TBL] [Abstract][Full Text] [Related]
18. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet.
Okada H; Takabatake R; Honda M; Takegoshi K; Yamashita T; Nakamura M; Shirasaki T; Sakai Y; Shimakami T; Nagata N; Takamura T; Tanaka T; Kaneko S
Oncotarget; 2017 Jun; 8(25):39978-39993. PubMed ID: 28591717
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
20. Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.
Zhang Y; Wang H; Xiao H
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
